

## CLAIMS

1. A heterodimeric antibody comprising:
  - a) a first monomer comprising an anti-CD3 scFv-linker-CH2-CH3, wherein said anti-CD3 scFv comprises a first variable heavy domain comprising a VHCDR1 of SEQ ID NO: 2, a VHCDR2 of SEQ ID NO: 3, and VHCDR3 of SEQ ID NO: 4; and a first variable light domain comprising a VLCDR1 of SEQ ID NO: 6, a VLCDR2 of SEQ ID NO: 7, and a VLCDR3 of SEQ ID NO: 8, and wherein said CH2-CH3 is a first Fc domain;
  - b) a second monomer comprising a VH-CH1-hinge-CH2-CH3, wherein VH is a second variable heavy domain and CH2-CH3 is a second Fc domain; and
  - c) a light chain comprising a second variable light domain,wherein said second variable heavy domain and said second variable light domain from a CD20 binding domain;  
wherein said second variable heavy domain comprises a VHCDR1 of SEQ ID NO:431, a VHCDR2 of SEQ ID NO:432, and a VHCDR3 of SEQ ID NO:433; and said second variable light domain comprises a VLCDR1 of SEQ ID NO:435, a VLCDR2 of SEQ ID NO:436, and a VLCDR3 of SEQ ID NO:437.
2. The heterodimeric antibody of claim 1, wherein said second variable heavy domain comprises SEQ ID NO:430.
3. The heterodimeric antibody of any one of claim 1 or claim 2, wherein said second variable light domain comprises SEQ ID NO:434.
4. The heterodimeric antibody of claim 1,  
wherein said first monomer comprises SEQ ID NO: 324;  
wherein said second monomer comprises SEQ ID NO: 323; and  
wherein said light chain comprises SEQ ID NO: 325.
5. The heterodimeric antibody of claim 1, wherein the Fc domains comprise an ablation variant of Fig 31.

6. The heterodimeric antibody of claim 1, wherein the first or second Fc domain comprises a pl variant of FIG 30.
7. The heterodimeric antibody of claim 1, wherein the first and second Fc domain comprise a set of amino acid substitutions of figure 29.
8. The heterodimeric antibody of claim 1, wherein the first and second Fc domain have a set of amino acid substitutions selected from the group consisting of: L368D/K370S : S364K; L368D/K370S : S364K/E357L; L368D/K370S : S364K/E357Q; T411E/K360E/Q362E : D401K; L368E/K370S : S364K; K370S : S364K; L368E/K370S : S364K/E357Q; K370S : S364K/E357Q;; L368E/K370S : S364K/E357Q; and K370S : S364K/E357Q, wherein the numbering is according to the EU index as in Kabat.
9. The heterodimeric antibody of claim 1, wherein said first Fc domain comprises the amino acid substitutions S364K/E357Q and said second Fc domain comprises the amino acid substitutions L368D/K370S, wherein the numbering is according to the EU index as in Kabat.
10. The heterodimeric antibody of claim 1, wherein CH1-hinge-CH2-CH3 of said second monomer comprises the amino acid substitutions N208D/Q295E/N384D/Q418E/N421D, wherein the numbering is according to the EU index as in Kabat.
11. The heterodimeric antibody of claim 1, wherein said first and second Fc domains each comprise the amino acid substitutions E233P/L234V/L235A/G236del/S267K, wherein the numbering is according to the EU index as in Kabat.
12. The heterodimeric antibody of claim 1, wherein said anti-CD3 scFv comprises a linker selected from FIG 33.
13. The heterodimeric antibody of claim 1, wherein the scFv comprises a linker (GKPGS)<sub>4</sub>.
14. A composition comprising:
- a) a first nucleic acid encoding the first monomer according to any one of claims 1-13;
  - b) a second nucleic encoding the second monomer according to any one of claims 1-13;
  - and

- c) a third nucleic acid encoding the light chain according to any one of claims 1- 13.
- 15. A composition comprising:
  - a) a first expression vector comprising said first nucleic acid of claim 14;
  - b) a second expression vector comprising said second nucleic acid of claim 14; and
  - c) a third expression vector comprising said third nucleic acid of claim 14.
- 16. A cell comprising:
  - a) a first nucleic acid encoding the first monomer according to any one of claims 1-13;
  - b) a second nucleic encoding the second monomer according to any one of claims 1-13;  
and
  - c) a third nucleic acid encoding the light chain according to any one of claims 1-13.
- 17. A cell comprising the composition of claim 14 or 15.
- 18. A cell expressing the heterodimeric antibody of any of claims 1-13.
- 19. A method of making a heterodimeric antibody comprising culturing the cell of any of claims 16-18 and isolating said heterodimeric antibody.
- 20. A pharmaceutical composition comprising the heterodimeric antibody of any one of claims 1-13.
- 21. The heterodimeric antibody of any one of claims 1-13 or the pharmaceutical composition of claim 20 for use in treatment of hematopoietic malignancies.
- 22. The heterodimeric antibody of any one of claims 1-13 or pharmaceutical composition of claim 20 for use in treatment of a cancer selected from a group consisting of: B cell lymphomas and leukemias, non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's Lymphoma (HL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, and chronic myeloid leukemia (CML).